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Neoangiogenesis and enhanced glucose metabolism in neoplasms are likely to be activated by the same biochemical stimulus;
hypoxia. A correlation between these two parameters has been postulated. The objective of this study was to evaluate the
relationship between Fluoro-desoxi-glucose uptake at positron emission tomography scan and angiogenesis in lung metastasis.
Fluoro-desoxi-glucose activity, expressed as a standard uptake value, and microvessel intratumoural density, were
retrospectively calculated in a series of 43 lung metastasis resected in 19 patients. Primary sites were colorectal cancer in
16 metastases, sarcoma in eight, gynaecological in four and other sites in 15. The correlation between the two parameters was
tested by logistic regression and multivariate analysis. Positron emission tomography scan was positive in 17 patients (sensitivity
89%). No correlation was observed between standard uptake value and microvessel intratumoural density in this series of lung
metastasis. Positron emission tomography negative and positive nodules presented comparable value of microvessel
intratumoural density (12.9 vs 11.3). Standard uptake value was signiﬁcantly correlated with nodules size and was higher in
colon cancer metastasis than in sarcoma ones. Microvessel intratumoural density was independent from nodule size but
signiﬁcantly higher in sarcoma than in colon cancer metastasis. The lack of correlation was conﬁrmed by multivariate analysis
after adjustment for tumour type and nodules size. The present study demonstrated that positron emission tomography scan
is positive in a high proportion of patients regardless of microvessel density. Glucose uptake and angiogenesis appear to be
independent biological features in lung metastasis. This observation may have implications for future antiangiogenic therapies.
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The increasing use of positron emission tomography (PET) scan in
management of different neoplastic diseases has brought great
improvement in the diagnosis and staging of cancer patients parti-
cularly in relation to the preoperative selection of surgical
candidates (Delbeke, 1999; Saunders et al, 1999).
Besides the staging implications of this new instrument, particu-
lar attention has recently been focused on the possible correlation
between neoplasms glucose uptake and other biological parameters
predictive of tumoural aggressiveness. Some investigators have
already observed the capacity of tumoural glucose uptake,
expressed by Standard Uptake Value (SUV), to predict tumour
metastatic power and worse prognosis in lung cancer (Younes et
al, 1997; Ahuja et al, 1998; Vansteenkiste et al, 1999) and other
neoplasms (Oshida et al, 1981; Nakata et al, 1997; Pasquali et al,
1998; Benard et al, 1999). Similarly a large number of studies have
documented a relationship between the angiogenic proﬁle of a
tumour (IMD) and its aggressiveness in NSCLC and other experi-
mental and human models such as colonic, breast, gastric, renal
and lung carcinomas (Harpole et al, 1996; Apolinario et al, 1997;
Weidner, 1998; Breast Cancer Progression Working Party, 2000).
In conclusion, even if these data are not conﬁrmed for soft tissue
sarcoma (Tomlinson et al, 1999), both SUV and IMD seem to
represent unfavourable prognostic factors in epiteliar tumours,
but their correlation has never been investigated.
Changes in the rate of glucose uptake and over-expression of
glucose transporters in cancer cells are likely to be associated with
adaptation to hypoxia in rapidly growing tumours (Kuiper et al,
1998), partly due to their increased dependency on glycolysis as
energy source (Vauperl et al, 1989). Otherwise hypoxia, which is
the result of a lack of perfusion and vascular compression by the
tumour, may also contribute to the enhanced expression of speciﬁc
angiogenic peptides and their receptors (Vauperl et al, 1989; Merral
et al, 1993; Kuiper et al, 1998). Therefore it can be postulated that
both angiogenesis and glucose metabolisms are activated by the
same biochemical stimulus: hypoxia.
At present, the histological microvessel density technique is the
gold standard (Fox, 1997) to characterise the degree of angiogenesis
(Vermeulen, 1996), but a non invasive, objective techniques for
preoperative assessment of tumoural vascularity, including glucose
metabolisms at PET scan, are under investigation (Fanelli et al,
1999). To identify the type of relationship between glucose metabo-
lism and neoangiogenesis may be of interest not only in the ﬁeld of
pulmonary metastases, but also in other neoplasms in order to
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angiogenic therapies (Ziche et al, 1999).
PATIENTS AND METHODS
Between September 1998 and December 1999, 19 patients with
lung metastases from different hystotypes underwent preoperatively
PET scan. At the time of surgery, a total of 43 nodules were
resected and proved to be metastatic. These cases represent 23%
of lung metastasectomies performed in the same period. Primary
sites were colorectal cancer in 16 nodules (10 patients), sarcoma
in eight nodules (four patients), gynaecological in four nodules
(two patients), other site in 15 nodules (three patients). Analysis
of angiogenesis included 12 additional nodules (10 sarcoma and
two colon) from three patients of the same population but resected
before PET scan examination. Table 1 describes the patients and
metastasis characteristics included in the analysis.
Images were acquired with a GE Advance PET scanner (General
Electric Medical Systems, Milwaukee, US, axial ﬁeld of view of
15 cm and resolution of approximately 5 mm). One hour after
injection of approximately 370 MbQ of [18F]FDG, each patient
was positioned supine on the tomographic bed with arms over
the head and a whole-body emission scan (5 min per bed position)
was started covering a ﬁeld of view from neck to pelvis. Transmis-
sion scan (3 min per bed position) was then performed on thorax
region to measure attenuation. Raw data were corrected for
measured attenuation using segmented transmission data (ref.
Bettinardi) and then reconstructed in transaxial images using an
iterative algorithm with 16 subset and order 4. Parametric SUV
transaxial images were obtained normalising each pixel for injected
dose and body weight as follows: SUV=(pixel-by-pixel activity in
Bq/cc)/(injected dose in MBq/body weight in kg). For the determi-
nation of the SUV, regions of interest (ROIs) were manually drawn
on transaxial images around the focal FDG-uptake area. No correc-
tion for partial-volume effect was performed. Maximum value of
mean SUV of different slices of each nodule was considered for
statistical analysis.
Positive nodules at PET scan were identiﬁed within the lung
during surgical resection to perform nodule speciﬁc correlation
between standard uptake value (SUV) and histological microvessel
density (IMD).
Surgical specimens were immunostained by a monoclonal anti-
body anti CD34 JC-70. Intratumoural capillaries and small
venules were identiﬁed and counted by light microscopy using
Chalkley counting, performed in three representative intratumour-
al and peritumoural areas of each slide in a 6200 field with a
lens of 0.86 mm diameter. The sum of Chalkley counting was
considered for statistical analysis. All the vessels counted determi-
nations were performed by the same pathologist blinded from
SUV data.
Statistical analysis
Analysis was conducted treating nodules as independent units of
observation because within-subject correlation on multiple nodules
was very low (Proc Mixed procedure in SAS, Cary, NC, USA).
Microvessel density (IMD), as sum of Chalkley counting, and maxi-
mum of mean standard uptake values (SUV) were used as
continuous variables. In addition, SUV values were regrouped into
negative (SUV=0) or positive (SUV40) values to assess the sensitiv-
ity of PET. Chi-square test and Fisher Exact Extension test were used
to compare the distribution of values across categorical variables.
Analysis of covariance was used to generate least square SUV means
adjusted by nodule size. Pearson product-moment and Spearman
rank correlations were calculated to assess the association between
angiogenesis and FDG-uptake variables, depending on compliance
with the normality assumption. In addition, multiple linear regres-
sion was used to adjust for nodule size when assessing the linear
association between glucose metabolism and angiogenesis. P-values
were derived from two-sided tests. A statistical signiﬁcant difference
was established if the associated P-value was 40.05.
RESULTS
PET scan was positive in 26 out of 43 metastases. Mean standard
uptake value (SUV) was 3.9+2.5 (median 3.6) with a range from
1.2 to 9.5 (Table 2). SUV increased with increasing nodule size (P-
value=0.0006), but no signiﬁcant correlation was observed between
SUV and nodule size when excluding PET negative nodules (P-
value=0.4). Standard uptake value was higher in colon metastases
than in sarcoma ones (3.04+2.09 vs 1.18+1.46), even though
statistical signiﬁcance was not reached (P=0.22).
As shown in Table 3, mean intratumoural microvessel density
was 11.9+3.7 (median 12), IMD was independent from nodule
size (P-value=0.89) being signiﬁcantly higher in sarcomas than in
colon cancer (mean microvascular density: 16.6+1.7 vs
10.2+3.2, respectively; P50.0001). In summary whilst colon
cancer metastases showed high glucose metabolism and low vascu-
lar density, sarcoma metastases had low activity at PET and high
vascular density.
No correlation was shown between glucose metabolism activity
and microvessel density (Table 4), even after having adjusted for
nodules size. Mean microvessel density in PET negative metastases
was comparable with that found in PET positive nodules
(12.9+3.9 vs 11.3+3.5 no signiﬁcant difference). Comparison of
the two variables by categorical versions of SUV did not reveal
any difference (P=0.68). The lack of a signiﬁcant correlation was
evident even when excluding PET negative nodules from the analy-
sis or after adjusting SUV data for nodule size, to exclude inﬂuence
of dimension on SUV data. When stratifying nodules by their size,
the correlation between microvessel density and SUV showed a
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Table 1 Patients and nodules characteristics
Solitary Multiple Overall
No patients 8 11 19
Male 5 5 10
Mean age (range) 61 (26–75)
No of metastasis 8 35 43
Mean mets/pts 1 3.1 2.3
No mets/histotype
Sarcoma 2 6 8
Colon 5 11 16
Others 1 18 19
Size
410 mm 2 10 12
11–15 mm 2 16 18
416 mm 4 9 13
Table 2 Standard uptake value
PET positive Overall
Mean+s.d. (range) Mean+s.d. (range)
SUV 3.9+2.5 (1.2–9.5) 2.4+2.8 (0–9.5)
SUV/size
410 mm 2.4+1.55 0.78+1.46
11–15 mm 3.54+2.66 1.67+2.54
416 mm 5.59+2.53 P-value 0.4 4.59+2.5 P-value 0.0006
SUV/histology
Sarcoma 2.36+1.1 1.18+1.46
Colon 3.74+1.6 3.04+2.09
Other 5.39+3.7 P-value 0.13 2.02+3.26 P-value 0.22
Angiogenesis and SUV correlation
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Similarly, assessment of the correlation between IMD and FDG–
SUV after having stratiﬁed nodules by histology did not result in
signiﬁcant differences.
Diagnostic value of PET scan was summarised in Table 4. Speci-
ﬁcity was not evaluable since only malignant lesions were analysed
in the present study. Overall sensitivity was 60% for nodules and
89% for patients. Only 33% of nodules smaller than 5 mm were
PET positive, but sensitivity increased to 55% for nodules between
5 and 10 mm and 94% for nodules greater than 15 mm (P-
value=0.0065). Sensitivity was higher for colon cancer metastases
than for sarcoma nodules (81% vs 50%) but size factor clearly
inﬂuenced these results, in fact sarcoma metastasis were signiﬁ-
cantly smaller than those from other types (12+8.7 mm vs
21.2+13.2; P=0.005). In sarcoma metastatic, vascular density
tended to be higher when multiple nodules were present per
patient (not signiﬁcant): mean IMD was 15.5+3.5 in patients with
one nodule only and 21.5+9.2 in patients with ﬁve nodules (two
patients).
DISCUSSION
In recent years a number of studies have demonstrated that the
ability of a tumour to induce proliferation of new blood vessels
has a profound effect on tumour growth, metastasis and prognosis
(Harpole et al, 1996; Apolinario et al, 1997; Weidner, 1998; Breast
Cancer Progression Working Party, 2000). Inhibition of angiogen-
esis and vascular targeting have become promising new anti-
cancer strategies. As pointed out by Aurerbach et al (1991)
‘perhaps the most consistent limitation of antiangiogenic research
is the availability of a simple, reliable, reproducible, quantitative
assay of the angiogenic response’. Although quantitative assess-
ment of tumour vascularization would be of major importance
as a prognostic factor and for the choice of therapeutic strategies,
for example as a way to select patients for clinical studies with
antiangiogenic agents, the optimal method for assessing it has
not been developed yet. At present, the most widely used method
is the assessment of intratumoural microvessel density through
immunohistochemical analysis with speciﬁc markers for endothe-
lial cells (Vermeulen et al, 1996). To overcome the labourious
nature of this method, the problem of the observer variation
and reproducibility and invasiveness of the procedure, some inves-
tigators have started to explore non-invasive, in vivo, imaging-
functional techniques to assess tumour vascularity, such as
doppler sonography (Ferrara et al, 2000), dynamic contrast
enhanced magnetic resonance imaging (Hawignorst et al, 1998),
functional CT technique (Miles et al, 2000) and radionuclide
imaging (Blankenberg et al, 2000). Even PET scan with FDG
has been considered as a way to measure blood ﬂow by assess-
ment of glucose metabolism enhancement, based on the
assumption that tumour inﬂux of the glucose analogue, and
therefore its uptake, should be proportional to blood ﬂow and
therefore to tumoural vascularity (Vermeulen et al, 1996), but
no studies have so far investigated this subject. We postulated
the existence of a relationship between neoangiogenesis and
enhanced glucose metabolism, basing our hypothesis on the biolo-
gical evidence that both neoangiogenesis and glucose metabolism
were activated by the same stimulus: hypoxia. In addition, the
clinical observation that these two variables may represent poor
prognostic factors, have been suggested by some authors as an
indirect factor of a potential link between the two variables.
Lung metastasis represent a favourable model to study neoan-
giogenesis and FDG–SUV, for the small size of nodules, the
easily measurable diameter, their regular margins and their position
within lung parenchima, faraway from major vessels, possible
source of interference with SUV and IMD data. In spite of these
advantages the main limit of this model is represented by the
heterogeneity of tumour types.
In contrast with common sense expectation, the main ﬁnding of
the current study was the lack of correlation between vascularity
and glucose metabolism.
To better understand this unexpected ﬁnding we analysed the
subgroups of different histotypes to verify if heterogeneity of
primary tumour could inﬂuence the result. Subgroup analysis led
to similar results. In addition, to eliminate the inﬂuence of nodule
size on SUV–IMD correlation we adjusted SUV by nodule size,
but no signiﬁcant result emerged.
The two main histotypes, colon and sarcoma metastasis, have
suggested an opposite biological behaviour: whilst sarcomas
showed high vascular density and low glucose activity, colon cancer
nodules presented low vascular density and high glucose activity.
The observed higher IMD in sarcoma than in carcinoma should
be taken with caution in spite of the P-value because of the limited
number of sarcoma cases and the method of counting metastases
from the same patient as separate observations.
These data suggest that neoangiogenesis and glucose metabolism
are independent factors and that PET scan is unable to predict
tumour angiogenic patterns in lung metastases. But further inves-
tigations about PET and angiogenesis are necessary for primary
lung neoplasms.
Although this conclusion would deny a speciﬁc capacity of PET
scan to predict response to antiangiogenic therapy, it does not
exclude the potential role of this technique in monitoring a
tumours response to standard anticancer therapy or to identify
recurrent or persistent disease after chemotherapy or radiotherapy
as suggested by some authors (Akhurst and Larson, 1999). The
functional property of PET imaging is its ability to evaluate
changes of tumour metabolism, beyond and maybe before anato-
mical modiﬁcations.
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Table 4 PET sensitivity in lung metastasis
Patients Nodules
PET+/No (%) PET+/No (%)
Overall sensitivity 17/19 89 27/43 60 P-value*
Sensitivity by nodule size**
55 mm 0 – 2/6 33
6–10 mm 1/2 50 3/6 50
11–15 mm 5/6 83 7/15 43
416 mm 11/11 100 15/16 94 0.0065
Sensitivity by histology
Sarcoma 4/4 100 4/8 50
Colon 8/10 80 13/16 81
Others 5/5 100 9/19 47 0.007
*Fisher Exact Extension association P-value. **Maximum nodule size was considered
for calculating sensitivity in patients with multiple nodules.
Table 3 Vascular density
PET pos Overall
Mean+s.d. (range) Mean+s.d. (range)
IMD 11.37+3.6 (6–18) 11.9+3.7 (6–18)
IMD/size
510 mm 9.7+4 12.4+4.3
11–15 mm 11.7+3.9 12.0+3.5
416 mm 11.5+3.6 P-value 0.7 11.5+3.6 P- value 0.84
IMD/histology
Sarcoma 16.5+2.4 16.6+1.7
Colon 10+3 10.2+3.2
Others 11+2.9 P-value 0.003 11.4+2.8 P-value 0.0001
Angiogenesis and SUV correlation
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in primary tumour growth and progression (Horak et al, 1992;
Weidner and Folkman, 1996) suggesting a relationship between size
of tumours and neoangiogenesis. In contrast with these ﬁndings,
our results in lung metastasis showed that microvessel density
was independent from nodule size. IMD tended to increase with
number of lung metastatic deposits in case of sarcoma metastasis,
suggesting that aggressiveness of the disease may not be related to
lung lesions size but to their number. These hypothesis would be in
accordance with previous observations that identiﬁed number of
metastases as an independent negative prognostic factor (Pastorino
et al, 1998). From a pathological point of view, the lower vascular
density of colon cancer metastasis in comparison with sarcoma
metastasis may be related to the intense central necrosis observed
in colon cancer metastasis but the biological and prognostic mean-
ing of these observations are not clear and only the follow up study
of this population may clarify this aspect in the future.
Contrasting results emerge from the literature on the relation-
ship between SUV and malignant nodule size. Brown et al (1999)
observed a correlation between FDG uptake and tumour diameter
in 23 lung cancers while Duhaylongsod et al (1995) didn’t ﬁnd any
correlation in 36 primary lung tumours. In the present study FDG
uptake measured by SUV was signiﬁcantly correlated with nodule
size when including both PET positive and negative metastases,
but no signiﬁcance was observed when only PET positive metas-
tases were considered for analysis (P-value=0.4). This information
should be taken into account when SUV is evaluated in clinical
studies, to avoid FDG activity being confounded by nodule size.
In addition it may contribute useful information when FDG meta-
bolism is investigated as a diagnostic and prognostic tool.
Although the high proportion of PET negative nodules in
this study does not compare favourably with previous reports,
PET was able to identify lung malignancy in 17 of the 19
patients with a sensitivity of 89%. If we consider the number
of nodules, PET scan showed an overall sensitivity of only
60%, proportional to tumour diameter: Thirty-three per cent
for nodules smaller than 5 mm, 55% for nodules between 5
and 10 mm and 94% for nodules greater than 15 mm (P-
value=0.0065). Sensitivity was higher for colon cancer than
sarcoma metastasis (81 vs 50%). But this data is inﬂuenced
by nodule size factor (being sarcoma metastasis signiﬁcantly
smaller than colon cancer). The reported data on PET scan
sensitivity represent preliminary results but the clinical role of
PET in lung metastases will be further studied and described
in a separate analysis.
In conclusion the observed lack of correlation between angio-
genic activity and glucose uptake in lung metastasis represents a
novel ﬁnding in cancer biology. PET scan seems unable to predict
angiogenic patterns of tumour in lung metastases but further inves-
tigations are necessary to conﬁrm these data on primary
neoplasms.
Note added in proof
Fluoro-desoxi-glucose activity, expressed as a standard uptake
value, and angiogenesis, expressed by microvessel intratumoural
density were retrospectively calculated in a series of 43 resected
lung metastasis. Uni- or multivariate analysis showed no correla-
tion between the two parameters. This observation may have
implications for future antiangiogenic therapies.
REFERENCES
Ahuja V, Coleman RE, Herndon J, Patz Jr EF (1998) The prognostic signiﬁ-
cance of ﬂuorodeoxyglucose positron emission tomography imaging for
patients with NSCLC. Cancer 83: 918–924
Akhurst T, Larson SM (1999) Positron Emission Tomography Imaging of
Colorectal Cancer. Seminars in Oncology 26(5): 577–583
Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dinge-
mans AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G (1997)
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins,
and neovascularization in patients with radically resected non-small-cell
lung cancer. J Clin Oncol 15(6): 2456–2466
Aurerbach R, Aurerbach W, Polakowski I (1991) Assay for angiogenesis: a
review. Pharmac Ther 51: 1–11
Benard F, Sternman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999)
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
J Nuc Med 40(8): 1241–1245
Blankenberg FG, Eckelman WC, Strauss HW, Welch MJ, Alavi A, Anderson
C, Bacharach S, Blasberg RG, Graham MM, Weber W (2000) Role of
radionuclide imaging in trials of antiangiogenic therapy. Acad Radiol 7:
851–867
Breast Cancer Progression Working Party (2000) Evidence for novel non-
angiogenenic pathway in breast-cancer metastases. Lancet 355: 1787–1788
Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl R (1999) Glucose
Transporters and FGD uptake in untreated primary human non small cell
lung cancer. J Nuclear Med 40(4): 556–565
Delbeke D (1999) Oncological application of FDG PET imaging. J Nucl Med
40(10): 1706–1715
Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG
(1995) Lung tumour growth correlate with glucose metabolism measured
by ﬂuoride-18 ﬂuorodeoxiglucose positron emission tomography. Ann
Thorac Surg 60: 1348–1352
Fanelli M, Locopo N, Gattuso D, Gasparini G (1999) Assessment of tumour
vascularization: immunohistochemical and non-invasive methods. Int J
Biological Markers 13(4): 218–231
Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA
(2000) Evaluation of tumour angiogenesis with US: imaging, Doppler,
and contrast agents. Acad Radiol 7: 824–839
Fox SB (1997) Tumour angiogenesis and prognosis. Histopathology 30: 294–
301
Harpole Jr DH, Richards WG, Herndon II JE, Sugarbaker DJ (1996) Angio-
genesis and molecular biologic substaging in patients with stage I non-
small cell lung cancer. Ann Thorac Surg May 61(5): 1470–1476
Hawignorst M, Knapstein PG, Knopp MV, Vaupel P, Van Kaick G (1998)
Uterine cervical carcinoma: comparison of standard and pharmacokinetic
analysis of time-intensity curves for assessment of tumour angiogensis and
patient survival. Cancer Res 58: 3598–3602
Horak ER, Leek R, Klenk N, Leteune S, Smith K, Stuart N, Greenall M,
Stepniewska K, Harris AL (1992) Angiogenesis, assessed by platelet/
endothelial cell adhesion molecule antibodies, an indicator of node metas-
tases and survival in breast cancer. Lancet 340: 1120–1124
Kuiper RAJ, Shellens JHM, Blijham GH, Beijnen JH, Voest EE (1998) Clinical
research on antiangiogenic therapy. Pharmacol Res 37: 1–16
Merral NW, Plevin R, Gould GW (1993) Growth factors, mitogens, omco-
genes and the regulation of Glucose transport. Cell Signal 5: 665–675
Miles KA, Charnsangave JC, Lee FT, Fishman EK, Horton K, Lee TY (2000)
Application of CT in the investigation of angiogenesis in oncology. Acad
Radiol 7: 840–850
Nakata B, Chung YS, Nishimura S, Mishihara T, Sakurai Y, Sawada T,
Okamura T, Kawabe J, Ochi H, Sowa M (1997) 18F-ﬂuorodeoxyglucose
positron emission tomography and the prognosis of patients with pancrea-
tic adenocarcinoma. Cancer 15; 79(4): 695–699
Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishi-
kura T, Imazeki K, Nakajima N (1981) Predicting the prognosis of breast
carcinoma patients with positron emission tomography using 2-deoxy-
2ﬂuoro (18F)-D-glucose. Cancer 82(11): 2227–2234
Pasquali C, Rubello D, Swperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin
G, Pedrazzoli S (1998) Neuroendocrine tumor imaging: can FDG PET
detect tumors with poor prognosis and aggressive behaviour. World J Surg
22(6): 588–592
Pastorino U, McCormack PM, Ginsberg RJ (1998) A new staging proposal for
pulmonary metastases. The results of analysis of 5206 cases of pulmonary
metastases. Surg Clin N Am 8(1): 197–202
C
l
i
n
i
c
a
l
Angiogenesis and SUV correlation
G Veronesi et al
1394
British Journal of Cancer (2002) 86(9), 1391–1395 ã 2002 Cancer Research UKSaunders CX, Dussek JE, O’Doherty MJ, Maisey MN (1999) Evaluation of
Fluorine-18-Fluorodesossiglucosie whole body positron emission tomo-
graphy imaging in the staging of lung cancer. Ann Thorac Surgery 69:
790–797
Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, Lee MC, Eilber F,
Nguyen M (1999) Different patterns of angiogenesis in sarcoma and carci-
nomas. Clin Cancer Res 5(11): 3516–3522
Vansteenkiste J, Stroobants SG, Dupont PJ, Verbeken EK, Deneffe GJ,
Mortelmans LA, Demedts MG the Leuven Lung Cancer Group (1999)
JCO 17: 3201–3206
Vauperl P, Kallinowski F, Okunieff P (1989) Blood ﬂow, oxigen and nutrient
supply, and metabolic microenvironment of human tumours: a review.
Cancer Res 49: 6449–6465
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella
F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantiﬁcation of
angiogenesis in human tumours: an international consensus on the meth-
odology and criteria of evaluation. Eur J Cancer 3214: 2474–2484
Weidner N (1998) Tumour vascularity as a prognostic factor in cancer
patients: the evidence continues to grow. J Pathology 184: 119–122
Weidner N, Folkman J (1996) Tumoral vascularity as a prognostic factor in
cancer. In:. Important advances in Oncology, De Vita VT, Hellman JR,
Rosenberg, SA (eds) pp 167–190. Philadelphia: Lippincott-Raven
Younes M, Brown R, Stephenson M, Gondo M, Cagle PT (1997) Overexpres-
sion of Glut1 and Glut2 in stage I NSCLC is associated with poor survival.
Cancer 80: 1046–1051
Ziche M, Sorriso C, Parenti A, Brogelli L, Tricarico C, Villari D, Pazzagli M
(1999) Biological parameter for the choice of antiangiogenic therapy and
efﬁcacy monitoring. Int J Biological Markers 14(4): 214–217
C
l
i
n
i
c
a
l
Angiogenesis and SUV correlation
G Veronesi et al
1395
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1391–1395